WO1997007798A1 - Pharmaceutical compounds - Google Patents
Pharmaceutical compounds Download PDFInfo
- Publication number
- WO1997007798A1 WO1997007798A1 PCT/US1996/013855 US9613855W WO9707798A1 WO 1997007798 A1 WO1997007798 A1 WO 1997007798A1 US 9613855 W US9613855 W US 9613855W WO 9707798 A1 WO9707798 A1 WO 9707798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- alkyl
- cryptophycin
- hydrogen
- Prior art date
Links
- 0 *CC(*)(*)C(CC(*)(*)C(*C(CC(*)C(*)C(N*C(O)=O)=O)C(*)C(*)*(*)[Al])=O)=O Chemical compound *CC(*)(*)C(CC(*)(*)C(*C(CC(*)C(*)C(N*C(O)=O)=O)C(*)C(*)*(*)[Al])=O)=O 0.000 description 8
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N CC(C)C[C@@H](C(O[C@@H](C/C=C/C(N[C@H](Cc(cc1Cl)ccc1OC)C(NCC1(C)C)=O)=O)[C@H](C)[C@H]2O[C@@H]2c2ccccc2)=O)OC1=O Chemical compound CC(C)C[C@@H](C(O[C@@H](C/C=C/C(N[C@H](Cc(cc1Cl)ccc1OC)C(NCC1(C)C)=O)=O)[C@H](C)[C@H]2O[C@@H]2c2ccccc2)=O)OC1=O LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- RDNUGONIMJOHAR-WOFDPGDDSA-N C[C@H]([C@H]1O[C@@H]1c1ccccc1)[C@H](C/C=C/C(N[C@H](Cc(cc1)cc(Cl)c1OC)C(NC[C@@H](C)C(O[C@H]1CC=C)=O)=O)=O)OC1=O Chemical compound C[C@H]([C@H]1O[C@@H]1c1ccccc1)[C@H](C/C=C/C(N[C@H](Cc(cc1)cc(Cl)c1OC)C(NC[C@@H](C)C(O[C@H]1CC=C)=O)=O)=O)OC1=O RDNUGONIMJOHAR-WOFDPGDDSA-N 0.000 description 1
- VUZBRBKYGIQXMP-UHFFFAOYSA-N Cc(cc1)cc(Cl)c1OC Chemical compound Cc(cc1)cc(Cl)c1OC VUZBRBKYGIQXMP-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- This invention relates to the fields of pharmaceutical and organic chemistry and provides novel cryptophycin compounds useful as anti-microtubule agents.
- Neoplastic diseases characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans and other mammals.
- Clinical experience in cancer chemotherapy has demonstrated that new and more effective drugs are desirable to treat these diseases.
- drugs which disrupt the microtubule system of the cytoskeleton can be effective in inhibiting the proliferation of neoplastic cells.
- the microtubule system of eucaryotic cells is a major component of the cytoskeleton and is a dynamic assembly and disassembly. Thus heterodimers of tubulin are polymerized and form microtubule.
- Microtubules play a key role in the regulation of cell architecture, metabolism, and division. The dynamic state of microtubules is critical to their normal function.
- tubulin is polymerized into microtubles that form the mitotic spindle.
- the microtubules are then depolymerized when the mitotic spindle's use has been fulfilled.
- agents which disrupt the polymerization or depolymerization of microtubules, and thereby inhibit mitosis comprise, some of the most effective cancer chemotherapeutic agents in clinical use.
- the compounds claimed herein possess fungicidal properties. Further, such agents having the ability to disrupt the microtubule system can be useful for research purposes.
- cryptophycin compounds are known in the literature; however, cryptophycin compounds having even greater solubility, robust potency are desired for most pharmaceutical uses and a broader library of cryptophycin compounds could provide additional treatment options.
- novel compounds providing such desired solubility as well compounds having the ability to disrupt the microtubule system.
- Such compounds can be prepared using total synthetic methods and are therefore well suited for development as pharmaceutically useful agents.
- the presently claimed invention provides novel cryptophycin compounds of Formula I
- Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C_-C_ 2 alkyl, C_-C_ 2 alkyne;
- R 1 is halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, or phosphate;
- R 2 is OH or SH; or R 1 and R 2 may be taken together to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring, or monoalkylphosphate ring; or R 1 and R 2 may be taken together to form a second bond between Cis and C 19 ;
- R 3 is a lower alkyl group;
- R 4 is H;
- R 5 is H;
- R 4 and R 5 may be taken together to form a second bond between Ci 3 and Ci 4 ,- R 6 is a substituent selected from the group consisting of B- ring heteroaromatic, substituted heteroaromatic, B-ring (C_-C 6 )alkyl, (C 3 -C 8 ) cycloalkyl, substituted C 3 -C 8 cycloalkyl, substituted (C_-C 6 ) alkyl, a group of the formula III":
- R 7 is selected from the group consisting of NR 51 R 52 , R 53 NR 5 l R 52 OR 53 , H and a lower alkyl group;
- R 51 and R 52 are independently selected from the group consisting of C 1 -C 3 alkyl;
- R 53 is C 1 -C 3 alkyl;
- R 8 is H or a lower alkyl group;
- R 7 and R 8 can optionally form a cyclopropyl ring;
- R 9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, and lower alkyl-C 3 -C5 cycloalkyl;
- R 10 is H or a lower alkyl group; R 9 and R 10 together optionally form a cyclopropyl ring;
- R 11 is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
- R 14 is H or a lower alkyl group
- R 15 , R 16 , and R 17 are each independently selected from the group consisting of hydrogen, (C_-C 6 )alkyl, OR 18 , halo,
- R 18 is selected from the group consisting of hydrogen, aryl, and C_-C 6 alkyl
- R 18 ' is selected from the group consisting of hydrogen and
- R 19 is C1-C6 alkyl
- R 19 ' is selected from the group consisting of hydrogen and (Ci-C ⁇ )alkyl
- R 23 is selected from the group consisting of hydrogen and (C_-
- R 30 is hydrogen or Ci-C ⁇ alkyl; n is 0, 1, or 2 p is 0, 1, or 2 . m is 0, 1, or 2 .
- X is selected from the group consisting of 0, NH and alkylamino
- Y is selected from the group consisting of 0, NH, and alkylamino
- Z is selected from the group consisting of -(CH 2 ) n _ ,
- ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof; provided that when R 6 is a group of Formula III" and n is 1, then at least one of the group consisting of R 15 , R l ⁇ and R 17 ust be a non-hydrogen group and if only one of R 15 , R 16 and R 17 is OH or OR 29 and one of the group consisting of R 15 , R 16 and R 17 is halo then the remaining member of the group consisting of R 15 , R 16 and R 17 must not be hydrogen or halo; R 29 is (C 1 -C 5 )alkyl; further provided that the compound is not a cryptophycin selected from the group consisting of cryptophycins:
- the present invention provides pharmaceutical formulations, a method for disrupting a microtubulin system using an effective amount of a compound of Formula I, a method for inhibiting the proliferation of mammalian cells comprising administering an effective amount of a compound of Formula I, and a method for treating neoplasia in a mammal comprising administering an effective amount of a compound of Formula I.
- the term "simple alkyl” shall refer to C 1 -C 7 alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain.
- Example ⁇ include, but are in no way limited to, methyl, ethyl, n-propyl, iso ⁇ propyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, methylated pentyl groups and the like.
- B-ring C ⁇ -C 6 alkyl refers to saturated, unsaturated, branched and straight chain alkyl wherein the B-ring C -Cgalkyl group may include up to three (3) non-carbon substituents.
- non-carbon substituents are most preferredly selected from the group consisting of OH, SCH phenyl, NH 2 , CO, CONH 2 , CO 2 H, PO 3 H 2 , SO 2 R 21 wherein R 21 is selected from hydrogen and C 1 -C 3 alkyl;
- substituted phenyl shall refer to a phenyl group with from one to three non- hydrocarbon substituents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I.
- substituted benzyl shall refer to a benzyl group with from one to three non- hydrocarbon substitutents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I wherein such substituents may be attached at any available carbon atom.
- B-ring heteroaromatic group refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur.
- B-ring heterocyclic groups are selected from, but not limited to, the group consisting of
- R 20 is selected from hydrogen and C_-C 6 alkyl. It is especially preferred that "B-ring heteroaromatic group” refers to a substituent selected from the group consisting of:
- cycloalkyl refers to a saturated Ci-Cs cycloalkyl group wherein such group may include from zero to three substituents selected from the group consisting of C 1 -C 3 alkyl, halo, and OR 22 wherein R 22 is selected from hydrogen and C 1 -C 3 alkyl. Such substituents may be attached at any available carbon atom. It is especially preferred that cycloalkyl refers to substituted or unsubstituted cyclohexyl.
- Lower alkoxy1 group means any alkyl group of one to five carbon atoms bonded to an oxygen atom.
- lower alkyl group means an alkyl group of one to five carbons and includes linear and non- linear hydrocarbon chains, including for example, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups.
- allylically substituted alkene means any alkene having from one to seven carbon atoms which contains an alkyl substitution on it.
- unsaturated lower alkyl means a lower alkyl group as defined supra , wherein from one to two double bonds are present in the unsaturated lower alkyl substituent.
- lower alkyl-C 3 ⁇ C 5 cycloalkyl refers to C-C alkyl substituted with a C 3 -C 5 cycloalkyl group.
- a preferred lower alkyl-C 3 -C 5 cycloalkyl group is -CH 2 -cyclopropyl; wherein the group is attached to the cryptophycin core structure at R 9 via the CH 2 .
- epoxide ring means a three- membered ring whose backbone consists of two carbons and an oxygen atom.
- aziridine ring means a three- membered ring whose backbone consists of two carbon atoms and a nitrogen atom.
- sulfide ring means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom.
- episulfide ring means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom.
- sulfate group means a five membered ring consisting of a carbon- carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom.
- cyclopropyl ring mean ⁇ a three member ring whose backbone consists of three carbon atoms.
- monoalkylphosphate ring means a five membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
- concise unsubstituted aromatic group refers to common aromatic rings having 4n ⁇ -2 electrons in a monocyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example but not limited to indolyl or naphthyl.
- simple substituted aromatic group refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group.
- heteromatic group refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur.
- halogen or “halo” refers to those members of the group on the periodic table historically known a ⁇ halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan.
- the term “mammal” shall refer to the Mammalia class of higher vertebrates.
- the term “mammal” includes, but is not limited to, a human.
- the term “treating” as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
- the cryptophycin compounds claimed herein can be useful for veterinary health purposes as well as for the treatment of a human patient.
- R 7 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, or isopentyl;
- R 7 is H, R 8 is methyl, R 3 is methyl, and X and Y are not both O; D) R 3 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl;
- R 9 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
- R 10 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or i ⁇ opentyl;
- G a cryptophycin compound wherein at least one of the groups selected from the group consisting of C- 3, C-6, C-7, C-10, C-16, C-17, and C-18 has R stereochemistry (numbering as set forth in Formula I supra . ) ;
- H a cryptophycin compound wherein at least one of the groups selected from the group consisting of C- 3, C-6, C-7, C-10, C-16, C-17, and C-18 has S stereochemi ⁇ try (numbering a ⁇ set forth in Formula I supra . ) ;
- Ar is phenyl with a sub ⁇ tituent selected from the group consisting of hydrogen, halogen, and simple alkyl; J) a compound wherein Y is 0; K) a compound wherein Y is 0, R 7 , R 8 , R 9 , and R 10 are each hydrogen; and R 1 and R 2 form an epoxide; L) R 7 , R 8 are each hydrogen;
- R 7 and R 8 are each selected from hydrogen and CH 3 ; N) Y is O;
- R is selected from the group consisting of methyl, ethyl, n-propyl, and phenyl; P) R 1 and R 2 form an epoxide ring;
- R 4 and R 5 form a double bond
- R 6 is substituted benzyl wherein one substituent is a halogen and one is an OR 12 group wherein R 12 is lower alkyl;
- R6 is ⁇ elected from the group consisting of
- Z) Z is -(CH2) n - wherein n is 0; AA) Z is -(CH2) n - wherein n is 2; BB) Z is -(CH2) n - wherein n is 1; CC) R 6 is Formula III';
- R 6 is Formula III' 1 ; EE) R 6 is C 3 -C 6 cycloalkyl;
- R 6 is selected from the group consisting of fi ⁇ ring heteroaromatic, substituted heteroaromatic, B-ring alkyl, cycloalkyl, substituted cycloalkyl, Formula III' and Formula III ' ' ;
- R 15 , R l ⁇ , and R 17 is selected from the group consisting of SCH 2 phenyl, NH 2 , CO, CONH 2 , CO 2 H, PO 3 H 2 , and SO 2 R 21 ' " wherein R 21 is selected from hydrogen and C 1 -C 3 alkyl;
- HH) Ar is phenyl
- R 6 i ⁇ a heteroaromatic ring
- MM R 7 is selected from the group consisting of N ( CH 3 ) 2 , CH 2 N ( CH 3 ) 2; NN) R 7 is CH 2 OCH 3 ;
- R 9 is CH 2 cyclopropyl
- R 3 is CH 3 ; R 4 and R 5 together form a second bond;
- R 14 is hydrogen;
- R 30 is hydrogen;
- R 7 and R 8 are each methyl;
- R 10 is hydrogen;
- R 9 is -CH 2 CH(CH3) 2 ;
- X and Y are each O;
- Ar is phenyl; and Ri R 2 - R-6
- Ar is instead of phenyl.
- the present invention provides a method of alleviating a pathological condition caused by hyperproliferating mammalian cells comprising administering to a subject an effective amount of a pharmaceutical or veterinary composition disclo ⁇ ed herein to inhibit proliferation of the cells.
- the method further comprises administering to the subject at least one additional therapy directed to alleviating the pathological condition.
- the pathological condition is characterized by the formation of neoplasm ⁇ .
- the neoplasms are selected from the group consi ⁇ ting of mammary, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS) , ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes pancreatic and esophageal, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin's disease and Hodgkin's disease neoplasms.
- CNS central nervous system
- neoplastic refers to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not ⁇ ubject to the u ⁇ ual limitations of growth.
- anti-neopla ⁇ tic agent i ⁇ any compound, compo i ion, admixture, co-mixture, or blend which inhibit ⁇ , eliminate ⁇ , retard ⁇ , or reverses the neoplastic phenotype of a cell.
- Anti-mitotic agents may be classified into three groups on the basi ⁇ of their molecular mechani ⁇ m of action.
- the first group consist ⁇ of agents, including colchicine and colcemid, which inhibit the formation of microtubules by sequestering tubulin.
- the second group consist ⁇ of agents, including vinblastine and vincristine, which induce the formation of paracry ⁇ talline aggregate ⁇ of tubulin.
- Vinblastine and vincristine are well known anticancer drugs: their action of di ⁇ rupting mitotic ⁇ pindle microtubule ⁇ preferentially inhibit ⁇ hyperproliferative cells.
- the third group consists of agents, including taxol, which promote the polymerization of tubulin and thus stabilizes microtubules.
- composition ⁇ containing a therapeutically effective amount of at lea ⁇ t one compound of Formula I, including the non-toxic addition salts thereof, which serve to provide the above recited benefits.
- compositions can also be provided together with physiologically tolerable liquid, gel, or solid carriers, diluents, adjuvants and excipients.
- physiologically tolerable liquid, gel, or solid carriers diluents, adjuvants and excipients.
- Such carriers, adjuvants, and excipients may be found in the U.S. Pharmacopeia, Vol. XXII and National Formulary vol XVII, U.S. Pharmacopeia Convention. Inc. Rockville, MD (1989) . Additional modes of treatment are provided in AHFS Dru ⁇ Information, 1993 e. by the American Hospital Formulary Service, pp. 522-660. Each of these references are well known and readily available to the skilled artisan.
- the present invention further provides a pharmaceutical composition used to treat neoplastic disease containing at least one compound of Formula I and at least one additional anti-neoplastic agent.
- Anti-neoplastic agents which may be utilized in combination with Formula I compounds include those provided in the Merck Index 11, pp 16-17, Merck & Co., Inc. (1989) .
- the Merck Index is widely recognized and readily available to the skilled artisan.
- antineoplastic agents may be antimetabolites which may include but are in no way limited to those selected from the group consisting of methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine, arabinoside, hydroxyurea, and 2- chlorodeoxyadeno ⁇ ine.
- the anti-neoplastic agents contemplated are alkylating agents which may include but are in no way limited to those ⁇ elected from the group consisting of cyclopho ⁇ phamide, mephalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard.
- the anti-neoplastic agents are plant alkaloids which may include but are in no way limited to those selected from the group consisting of vincristine, vinblastine, taxol, and etoposide.
- the anti-neoplastic agents contemplated are antibiotic ⁇ which may include, but are in no way limited to tho ⁇ e ⁇ elected from the group consisting of doxorubicin, daunorubicin, mitomycin C, and bleomycin.
- the anti-neoplastic agents contemplated are hormones which may include, but are in no way limited to those selected from the group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane.
- the anti-neoplastic agents contemplated include enzymes which may include, but are in no way limited to tho ⁇ e ⁇ elected from the group con ⁇ i ⁇ ting of L- A ⁇ pargina ⁇ e and aminoacridine derivative ⁇ ⁇ uch as, but not limited to, amsacrine.
- Additional anti-neoplastic agents include those provided by Skeel, Roland T., "Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents" Handbook of Cancer Chemotheranv (3rd ed. ) , Little Brown & Co. (1991) . These compounds and compositions can be administered to mammals for veterinary use.
- the dosage required for therapeutic effect will vary according to the type of use, mode of administration, as well as the particularized requirements of the individual hosts. Typically, dosages will range from about 0.001 to 1000 mg/kg, and more usually 0.01 to 10 mg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits are obtained.
- drug dosage as well as route of administration, must be selected on the basis of relative effectivenes ⁇ , relative toxicity, growth characteristics of tumor and effect of Formula I compound on cell cycle, drug pharmacokinetics, age, sex, physical condition of the patient and prior treatment, which can be determined by the skilled artisan.
- the compound of Formula I may be formulated into therapeutic compositions as natural or salt forms.
- Pharmaceutically acceptable non-toxic salts include base addition salts which may be derived from inorganic bases such as for example, ⁇ odium, potassium, ammonium, calcium, or ferric hydroxides, and such organic base ⁇ a ⁇ isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as for example, hydrochloric or phosphoric acids or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Additional excipients which further the invention are provided to the skilled artisan for example in the U.S. Pharmacopeia .
- anti- neoplastic compositions may be formulated for oral administration. Such compositions are typically prepared as liquid solution or suspen ⁇ ions or in solid forms. Oral formulation usually include such additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions may take the form of solution ⁇ , suspension ⁇ , tablet ⁇ , pills, capsules, ⁇ u ⁇ tained relsease formulations, or powders, and typically contain 1% to 95% of active ingedient.
- compositions of the present invention may be prepared as injectables, either as liquid solutions, suspensions, or emulsion ⁇ ; ⁇ olid form ⁇ suitable for solution in or suspension in liquid prior to injection. Such injectables may be administered subcutaneously, intravenously, intraperitoneally, intramuscularly, intrathecally, or intrapleurally.
- the active ingredient or ingredients are often mixed with diluents, carriers, or excipients which are physiologically tolerable and compatible with the active ingredient (s) .
- Suitable diluent ⁇ and excipients are for example, water, saline, dextrose, glycerol, or the like and combinations thereof.
- the compositions may contain minor amounts of auxilary ⁇ ubstances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
- the invention further provides methods for using
- a preferred embodiment i ⁇ a method to inhibit the proliferation of hyperproliferative mammalian cell ⁇ .
- hyperproliferative mammalian cells are mammalian cells which are not subject to the characteristic limitations of growth (programmed cell death for example) .
- a further preferred embodiment is when the mammalian cell is human.
- the invention further provides contacting the mammalian cell with at least one Formula I compound and at least one anti-neoplastic agent. The types of anti-neopla ⁇ tic agents contemplated are discussed supra .
- the invention further provides methods for using a compound of Formula I to inhibit the proliferation of hyperproliferative cell ⁇ with drug-resistant phenotypes, including those with multiple drug-resi ⁇ tant phenotypes, by contacting said cell with a compound of Formula I in an amount sufficient to inhibit the proliferation of a hyperproliferative mammalian cell.
- a preferred embodiment is when the mammalian cell is human.
- the invention further provides contacting a Formula I compound and at least one additional anti-neoplastic agent, discussed supra .
- the invention provides a method for alleviating pathological conditions caused by hyperproliferating mammalian cells for example, neoplasia, by administering to a subject an effective amount of a pharmaceutical composition containing Formula I compound to inhibit the proliferation of the hyperproliferating cell ⁇ .
- pathological condition refers to any pathology arising from the proliferation of mammalian cells that are not subject to the normal limitations of growth. Such proliferation of cells may be due to neoplasms as discussed supra .
- the neoplastic cells are human.
- the present invention provides methods of alleviating ⁇ uch pathological conditions utilizing a compound of Formula I in combination with other therapies, as well as other anti-neoplastic agents.
- Twofold dilution ⁇ are made with sterile distilled water/10 percent DMSO to obtain final drug concentrations in the agar dilution assay plates ranging from 0.008 ⁇ g/ml to 16.0 ⁇ g/ml against an expanded panel of 84 Cryptococcus neoformans strains.
- Cryptococcus neoformans isolates is determined to illustrate the desired antifungal activity.
- the compounds are screened for minimum inhibitory concentrations against KB, a human nasopharyngeal carcinoma cell line, LoVo, a human colorectal adenocarcinoma cell line using The Corbett assay, see Corbett, T.H. et al. Cvtotoxic Anticancer Dru ⁇ s: Models and Concepts for Dru ⁇ Discovery and Developmen . pp 35-87, Kluwer Academic Publisher ⁇ : Norwell, 1992. see also, Valeriote, et al. Discovery and Development of Anticancer Agents; Kluwer Academic Publisher ⁇ , Norwell, 1993 i ⁇ used for the evaluation of compounds.
- the most active compounds are further evaluated for cytotoxicity against four different cell types, for example a murine leukemia, a murine solid tumor, a human solid tumor, and a low malignancy fibroblast using the Corbett assay.
- the compounds are further evaluated against a broad spectrum of murine and human tumors implanted in mice, including drug resi ⁇ tant tumors.
- Tumor burden (mean tumor burden in treated animals versus mean tumor burden in untreated animals) are used as a further as ⁇ essment. T/C values that are less than 42% are considered to be active by National Cancer Institute Standards; T/C values less than 10% are considered to have excellent activity and potential clinical activity by National Cancer Institute standards. Materials
- Vinblastine Vinblastine, cytochalasin B, tetramethylrhodamine isothiocyanate (TRITC) -phalloidin, sulforhodamine B (SRB) and antibodies against ⁇ -tubulin and vimentin are commercially available from recognized commercial vendors.
- BME Basal Medium Eagle containing Earle ' s salts
- FBS Fetal Bovine Serum
- the Jurkat T cell leukemia line and A-10 rat aortic smooth muscle cells are obtained from the American Type Culture Collection and are cultured in BME containing 10% FBS and 50 ⁇ g/mL gentamycin sulfate.
- Human ovarian carcinoma cell ⁇ (SKOV3) and a sub-line which has been selected fro re ⁇ i ⁇ tance to vinbla ⁇ tine (SKVLBl) were a generou ⁇ gift from Dr. Victor Ling of the Ontario Cancer Institute. Both cell lines are maintained in BME containing 10% FBS and 50 ⁇ g/mL gentamycin sulfate.
- Vinblastine is added to a final concentration of l ⁇ g/mL to SKVLBl cells 24 hours after pas ⁇ age to maintain selection pressure for P-glycoprotein- overexpressing cells.
- Cell proliferation as ⁇ ay ⁇ are performed as described by Skehan et al .
- cultures are treated with the indicated drugs as described in Skehan and total cell numbers are determined by counting the cells in a hemacytometer.
- the percentage of cells in mitosis are determined by staining with 0.4% Giemsa in PBS followed by rapid wa ⁇ he ⁇ with PBS.
- At least 1000 cells per treatment are scored for the presence of mitotic figures and the mitotic index is calculated as the ration of the cells with mitotic figures to the total number of cells counted.
- A-10 cells are grown to near-confluency on glass coverslips in BME/10% FBS. Compounds in PBS are added to the indicated final concentrations and cells are incubated for an additional 24 hours. For the staining of microtubules and intermediate filaments, the cells are fixed with cold methanol and incubated with PBS containing 10% calf serum to block nonspecific binding sites. Cells are then incubated at 37"C for 60 min. with either monoclonal anti- ⁇ -tubulin or with monoclonal anti-vimentin at dilutions recommended by the manufacturer. Bound primary antibodies are subsequently visualized by a 45-minute incubation with fluorescein- conjugated rabbit antimouse IgG.
- the coverslips are mounted on microscope slides and the fluorescence patterns are examined and photographed using a Zeiss Photomicroscope 111 equipped with epifluorescence optics for fluore ⁇ cein.
- a Zeiss Photomicroscope 111 equipped with epifluorescence optics for fluore ⁇ cein.
- cells are fixed with 3% paraformaldehyde, permeabilized with 0.2% Triton X-100 and chemically reduced with sodium borohydride (Img/ML) .
- PBS containing lOOnM TRITC-phalloidin is then added and the mixture is allowed to incubate for 45 min. at 37 'C.
- the cells are washed rapidly with PBS before the coverslips are mounted and immediately photographed a ⁇ de ⁇ cribed above.
- Dose-re ⁇ pon ⁇ e curve ⁇ for the effect ⁇ of cryptophycin compounds and vinblastine on cell proliferation and the percentage of cells in mitosis are determined.
- Aortic smooth muscle (A-10) cells are grown on glass coverslip ⁇ and treated with PBS, 2 ⁇ M cytochala ⁇ in B, lOOnM vinbla ⁇ tine or lOnM cryptophycin compounds . After 24 hours, microtubules and vimentin intermediate filaments are visualized by indirect immunofluorescence and microfilaments are stained using TRITC - phalloidin. The morphological effects of each drug is examined. Untreated cells displayed extensive microtubule networks complete with perinuclear microtubule organizing centers. Vimentin intermediate filaments were also evenly distributed throughout the cytoplasm, while bundles of microfilaments were concentrated along the major axis of the cell.
- Cytochalasin B cau ⁇ ed complete depolymerization of microfilaments along with the accumulation of paracrystalline remnants. This compound did not affect the distribution of either microtubules or intermediate filaments. The cryptophycin treated microtubules and vimentin intermediates are observed for depletion of microtubules, and collapse of rimentin intermediate filaments.
- A-10 cells are treated for 3 hours with 0 or 10 ⁇ M taxol before the addition of PBS, lOOnM vinblastine or lOnM cryptophycin compound.
- microtubule organization i ⁇ examined by immunofluorescence as described above.
- microtubule ⁇ in taxol-treated cell ⁇ were extensively bundled, especially in the cell polar regions.
- vinblastine caused complete depolymerization of microtubules non-pretreated cells.
- pretreatment with taxol prevented microtubule depolymerization in respon ⁇ e to vinblastine.
- microtubules pretreated with taxol are observed with cryptophycin treatment.
- A-10 cells are treated with either lOOnM vinblastine or lOnM cryptophycins for 24 hr., re ⁇ ulting in complete microtubule depolymerization.
- the cell ⁇ are then wa ⁇ hed and incubated in drug-free medium for period ⁇ of 1 hour or 24 hour ⁇ .
- Microtubule ⁇ repolymerized rapidly after the removal of vinbla ⁇ tine, ⁇ howing significant levels of microtubules after 1 hour and complete morphological recovery by 24 hour.
- Cells are visualized for microtubule state after treatment with a cryptophycin compound of this invention at either 1 hour or 24 hours after removal of the cryptophycin compounds.
- SKOV3 cells are treated with combinations of cryptophycins and vinblastine for 48 hours. The percentages of surviving cells are then determined and the IC 50 S for each combination is calculated.
- SKVLBl cells are resistant to natural product anticancer drugs because of their over expression of P-glycoprotein.
- Taxol caused dose-dependent inhibition of the proliferation of both cell lines with IC 50 S for SKOV3 and SKVLBl cells of 1 and 8000nM, respectively.
- Vinblastine also inhibited the growth of both cell lines, with IC 50 S of 0.35 and 4200nM for SKOV3 and SKVLBl cells, re ⁇ pectively.
- Cryptophycin ⁇ compounds of this invention demonstrate activity with an IC 50 S of from about 1 to about 1000pm for SKOV3 and SKVLBl cell ⁇ .
- the present invention provides novel cryptophycin compounds which are potent inhibitors of cell proliferation, acting by disruption of the microtubule network and inhibition of mitosis.
- These studie ⁇ can illustrate that cryptophycin compounds disrupt microtubule organization and thus normal cellular functions, including those of mitosi ⁇ .
- Cla ⁇ sic anti-microtubule agents such as colchicine and
- Vinca alkaloids arrest cell division at mitosi ⁇ . It seems appropriate to compare the effect of one of these agent ⁇ on cell proliferation with the cryptophycin compounds.
- Vinca alkaloid vinblastine was selected as representative of the classic anti-microtubule agents. Accordingly, the effect of cryptophycin compounds and vinblastine on the proliferation and cell cycle progression of the Jurkat T-cell leukemia cell line is compared.
- GC3 human colon carcinoma cells (1x10 cells in lOO ⁇ l as ⁇ ay medium/well) twenty four hour ⁇ prior to test compound addition.
- Cell free assay medium was added to other select wells of the 96 well plate.
- the assay medium (RPMI-1640 was the medium used; however, any medium that will allow the cells to survive would be acceptable) was supplemented with 10% dialyzed fetal bovine serum and 25 mM HEPES buffer.
- test compound was stored in an amber bottle prior to testing.
- Fresh dimethylsulfoxide stock solution 200 ⁇ g/ml was prepared immediately prior to preparation of test sample dilutions in phosphate-buffered saline (PBS) .
- a dilution of 1:20 dimethylsulfoxide solution in PBS was prepared such that the final concentration was 10 ⁇ g/ml.
- Serial 1:3 dilutions using PBS (.5ml previous sample of 1ml PBS) were prepared.
- Falcon 2054 tubes were used for the assay.
- a lOul sample of each dilution of test compound was added in triplicate to wells of GC3 plates. The plates were incubated for 72 hours at about 37 C. A 10 ⁇ l sample of stock 3- [4, 5-dimethyl-2-yl] -2, 5-diphenyltetrazolium bromide salt ("MTT" 5 mg/ml in PBS) was added to each well. The plates were incubated for about an hour at 37 C. The plates were centrifuged, media was decanted from the wells and lOO ⁇ l acid-isopropanol (0.04 N HCl in i ⁇ opropanol) was added to each well. The plate was read within one hour using a te ⁇ t wavelength of 570nm (SpectraMax reader) .
- Ar, R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 have the meanings set for supra in Formula I.
- R 13 is selected from the group consi ⁇ ting of t-butylcarbamate (BOC) ;
- R 24 is selected from the group consi ⁇ ting of
- N-hydroxy ⁇ uccinimide herein "NHS”
- N-hydroxysulfosuccinimide and salts thereof, 2-nitrophenyl, 4- nitrophenyl, and 2, 4-dichlorophenyl
- X i ⁇ O NH or alkylamino
- Y is 0, NH, or alkylamino.
- R 25 is an active ester substituent; with an acid of the formula
- R 27 is ⁇ elected from the group consisting of H, C_-C_2 alkyl, and aryl; and a silylating agent.
- active ester substituent refers to a sub ⁇ tituent which makes the OR 24 sub ⁇ tituent a good leaving group.
- Appropriate ⁇ ubstituents can be selected with guidance from standard reference guides, for example, “Protective Groups in Organic Chemistry”, Plenum Press, (London and New York, 1973); Greene, T.W. "Protecting Group ⁇ in Organic Synthesis", Wiley (New York, 1981).
- An especially preferred R 25 group is N-hydroxy-succinimide. (NHS)
- Formula I contains an amine, then the amine substituent of the R 6 group must be protected using an amino protecting group.
- an amino protecting group The artisan can readily select an appropriate amino protecting group using guidance from standard works, including, for example, “Protective Groups in Organic Chemistry”, Plenum Press, (London and New York, 1973); Greene, T.W. "Protecting Groups in Organic Synthesis", Wiley (New York, 1981) .
- R 27 should be a group that allows for the removal of the -CO 2 R 27 substituent using acidic, neutral, or mild basic conditions.
- Preferred R 27 groups include, but are in no way limited to, hydrogen, C_-C 6 alkyl, tricholoromethyl, trichloroethyl, and methylthiomethyl. It is especially preferred that R 27 is hydrogen. To provide further guidance for the artisan, the following schemes are provided:
- R 1 ' is halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, phosphate or a protected OH or protected SH group;
- R 2 is OH or SH;
- R 26 i ⁇ an alcohol protecting group introduced during a portion of the ⁇ ynthetic proce ⁇ to protect an alcohol group which might otherwi ⁇ e react in the course of chemical manipulations, and is then removed at a later stage of the synthesis.
- R 6 has the meaning def ined supra .
- the ester starting material can be prepared, for example, as follows:
- R 6 has the meaning def ined supra .
- the ⁇ cheme for preparing the ester is further explained by the Preparation Section herein which provides one specific application of the scheme for the convenience of the skilled artisan.
- the Scheme for preparing the ester is applicable to the Ar substituents claimed herein.
- the scheme illustration is not intended to limited the synthesis scheme only to the phenyl ring illustrated. Rather, the artisan can broadly apply this process to provide desired starting materials for the compounds claimed herein.
- the necessary reaction time is related to the starting materials and operating temperature.
- the optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by ⁇ hort reaction times, and maximum yield, which is favored by long reaction times.
- Step 1 Methyl 5-Phenylpent-2 ( E) -enoate.
- a solution of trimethyl phosphonoacetate (376 g, 417 mL, 2.07 mol) in THF (750 mL) was stirred at 0 °C in a 3L 3-neck round bottom flask equipped with a mechanical stirrer and N2 inlet.
- To the chilled solution neat tetramethyl guanidine (239 g, 260 mL, 2.07 mol) was added dropwise via an addition funnel. The chilled clear pale yellow solution was stirred for 25 minute ⁇ at 0 °C.
- Step 2 5-phenyl-pent-2-en-l-ol.
- a solution of enoate e ⁇ ter 310.5 g, 1.5 mol
- THF 1.5 L
- DIBAL 2.5 L, 1.5 M in toluene, 3.75 mol
- EIMS m/z 162 (1:M+) 144 (16), 129 (7), 117 (9) 108 (6), 92 (17), 91 (100), 75 (5), 65 (12), HREIMS m/z 162, 1049 (CnHi4 ⁇ , D -0.4 mmu) ; UV lmax (e) 206 (9900), 260 (360); IR nmax 3356, 2924, 1603, 1496, 1454, 970, 746, 700 cm- 1 ; NMR d 7.15-7.3 (Ph-H5;m), 5.70 (3-H;dt, 15.6/6.0), 5.61 (2-H;dt, 15.6/4.8), 4.02 (1-H2;d 4.8) , 2.68 (5-H2; t, 7.2), 2.40 (OH;b ⁇ ), 2.36(4-H2; dt, 6.0/7.2); 13 C NMR dl41.6 (Ph i 1 ), 131.8(3), 129.5 (2), 128.3/128.2
- the resulting mixture was cooled to -20 °C and treated with Ti(0-i-Pr) 4 (9.2 mL, 0.031 mol), followed by the addition of t-butylhydroperoxide (4.0 M in CH 2 CI 2 , 182 mL, 0.78 mol) at a rate to maintain the temperature ⁇ -20 °C.
- t-butylhydroperoxide 4.0 M in CH 2 CI 2 , 182 mL, 0.78 mol
- the reaction mixture was stirred for another 30 min, and then treated with a solution of the allylic alcohol (50 g, 0.31 mol) in CH 2 CI 2 (30 mL) at a rate to maintain the temperature ⁇ -20 °C.
- the reaction was stirred at the same temperature for 5 h, then filtered into a solution of ferrous sulfate heptahydrate (132 g) and tartaric acid (40 g) in water (400 mL) at 0 °C. The mixture was stirred for 20 min, then transferred to a separatory funnel and extracted with t-BuOMe (2x200 mL) . The combined organic phase was stirred with 30% NaOH solution containing NaCl, for 1 h at 0 °C. The layers were again separated, and the aqueous phase extracted with t-BuOMe. The combined organic phase was washed with brine, dried over MgS0 4 and concentrated to yield 52.8 g as an amber oil.
- the crude aldehyde from above was dis ⁇ olved in THF (90 mL) and treated with trimethyl phosphonoacetate (9.03 mL, 55.8 mmol) and tetramethylguanidine (7.0 mL, 55.8 mmol) at room temperature under nitrogen.
- the reaction mixture was stirred for 16 h, then partitioned between EtOAc (200 mL) and water (100 mL) .
- the aqueous phase was back extracted with EtOAc (100 mL) , and the combined organic phase was washed with water, brine and dried over Na2S ⁇ 4 .
- Methyl ester (2.673 mmol) was dis ⁇ olved in acetone and then IN aqueous LiOH (26mL) added at room temperature. The cloudy mixture was further diluted with acetone (20mL) and the re ⁇ ulting yellow mixture stirred at room temperature for 23.5h. The reaction was diluted with diethylether (400mL) and the organics washed with IN HCl (120mL) , brine (200mL) and H 2 O (160mL) .
- Boc amine as prepared by Example 2 (109mg,0.154mmol) was dis ⁇ olved in trfluoracetic acid (5mL,5mM) and ⁇ tirred at room temperature for 2h. The reaction was concentrated in vacuo and dried under high vacuum to give the trifluoroacetate salt of amine as a light brown foam. Crude amine salt (max. 0.154mmol) was dissolved in dry DMF (31mL) and dusopropylethylamine (80uL, 0.462mmol) , followed by pentafluorophenyl diphenyl -phosphinate (77mg, 0.2mmol) added.
- Styrene prepared as described by Example 3 (42mg, 0.0712mmol) was suspended in dry dichloromethane (2.2mL, 0.035mM) and mCPBA (49mg, 0.285mmol) added in one portion at room temperature. Dry tetrahydrofuran (0.3mL) was added to produce a homogeneous solution. The reaction was stirred under N at room temperture for 21h and then diluted with further CH 2 CI 2 (15mL) . Organics were washed with 10% aq. Na 2 S 2 ⁇ s (lOmL), sat. aq.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96929780A EP0850057A4 (en) | 1995-08-30 | 1996-08-30 | Pharmaceutical compounds |
BR9610214A BR9610214A (en) | 1995-08-30 | 1996-08-30 | Pharmaceutical compounds |
AU69048/96A AU6904896A (en) | 1995-08-30 | 1996-08-30 | Pharmaceutical compounds |
JP9510549A JP2000501067A (en) | 1995-08-30 | 1996-08-30 | Pharmaceutical compounds |
AU43300/97A AU4330097A (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compounds |
JP10511080A JP2001502297A (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compounds |
EP97941379A EP0957912A1 (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compounds |
PCT/US1997/015245 WO1998008506A1 (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compounds |
CA002263420A CA2263420A1 (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compounds |
MXPA/A/1998/001604A MXPA98001604A (en) | 1995-08-30 | 1998-02-27 | Farmaceuti compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US293595P | 1995-08-30 | 1995-08-30 | |
US60/002,935 | 1995-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997007798A1 true WO1997007798A1 (en) | 1997-03-06 |
Family
ID=21703268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/014670 WO1997008334A1 (en) | 1995-08-30 | 1996-08-30 | Cryptophycins from aberrant biosynthesis |
PCT/US1996/013855 WO1997007798A1 (en) | 1995-08-30 | 1996-08-30 | Pharmaceutical compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/014670 WO1997008334A1 (en) | 1995-08-30 | 1996-08-30 | Cryptophycins from aberrant biosynthesis |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP0850316A4 (en) |
JP (2) | JP2000501067A (en) |
AU (2) | AU709828B2 (en) |
BR (1) | BR9610214A (en) |
CA (2) | CA2246117A1 (en) |
WO (2) | WO1997008334A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009601A2 (en) * | 1996-09-06 | 1998-03-12 | Eli Lilly And Company | Process to prepare pharmaceutical compounds |
WO1998009974A1 (en) * | 1996-09-06 | 1998-03-12 | Eli Lilly And Company | Process and novel intermediates |
EP0861838A2 (en) * | 1997-02-26 | 1998-09-02 | Eli Lilly And Company | Process and intermediates for preparing cryptophycin compounds |
EP0869786A1 (en) * | 1995-12-22 | 1998-10-14 | Eli Lilly And Company | Pharmaceutical compounds |
EP0932601A1 (en) * | 1996-08-30 | 1999-08-04 | Eli Lilly And Company | Process for preparing pharmaceutical compounds |
EP0934065A1 (en) * | 1996-08-30 | 1999-08-11 | Eli Lilly And Company | Pharmaceutical compounds |
EP0957912A1 (en) * | 1996-08-30 | 1999-11-24 | Eli Lilly And Company | Pharmaceutical compounds |
EP0975610A1 (en) * | 1997-02-26 | 2000-02-02 | Eli Lilly And Company | Tripeptide and tetrapeptide pharmaceutical compounds |
US6103913A (en) * | 1998-10-16 | 2000-08-15 | Eli Lilly And Company | Process for preparing enollactone derivatives |
US6376230B1 (en) | 1998-10-16 | 2002-04-23 | Eli Lilly And Company | Stereoselective process for producing intermediates of cryptophycins |
WO2003077906A1 (en) * | 2002-03-18 | 2003-09-25 | Nihon University | Cyclic etheramine derivatives as medicaments for malignant tumors |
US6680311B1 (en) | 1996-08-30 | 2004-01-20 | Eli Lilly And Company | Cryptophycin compounds |
EP1751279A2 (en) * | 2004-05-05 | 2007-02-14 | Regents Of The University Of Minnesota | Nucleic acids and polypeptides involved in the production of cryptophycin |
EP2266607A2 (en) | 1999-10-01 | 2010-12-29 | Immunogen, Inc. | Immunoconjugates for treating cancer |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008334A1 (en) * | 1995-08-30 | 1997-03-06 | University Of Hawaii | Cryptophycins from aberrant biosynthesis |
EP0870501A1 (en) * | 1997-04-11 | 1998-10-14 | Eli Lilly And Company | Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections |
EP0870506A1 (en) * | 1997-04-11 | 1998-10-14 | Eli Lilly And Company | Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer |
US6180679B1 (en) * | 1998-04-07 | 2001-01-30 | Eli Lilly And Company | Method for treating fungal infections |
WO2007000994A1 (en) * | 2005-06-28 | 2007-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method of producing compound having anti-hcv action |
CN103724290B (en) * | 2013-11-15 | 2015-04-29 | 浙江大学 | Cyclopeptide compound clavatustide A as well as producing strain, preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868208A (en) * | 1988-07-15 | 1989-09-19 | Merck & Co., Inc. | Antifungal agent and method |
US4946835A (en) * | 1988-07-15 | 1990-08-07 | Merck & Co., Inc. | Antifungal fermentation product and method |
US4845085A (en) * | 1988-08-09 | 1989-07-04 | Merck & Co., Inc. | Antifungal agent |
US4845086A (en) * | 1988-08-09 | 1989-07-04 | Merck & Co., Inc. | Antifungal agent |
US5952298A (en) * | 1993-12-21 | 1999-09-14 | The University Of Hawaii | Cryptophycins |
JP4181632B2 (en) * | 1995-03-07 | 2008-11-19 | ユニバーシティ オブ ハワイ | New synthetic cryptophycins |
WO1997008334A1 (en) * | 1995-08-30 | 1997-03-06 | University Of Hawaii | Cryptophycins from aberrant biosynthesis |
-
1996
- 1996-08-30 WO PCT/US1996/014670 patent/WO1997008334A1/en not_active Application Discontinuation
- 1996-08-30 WO PCT/US1996/013855 patent/WO1997007798A1/en not_active Application Discontinuation
- 1996-08-30 EP EP96932217A patent/EP0850316A4/en not_active Withdrawn
- 1996-08-30 EP EP96929780A patent/EP0850057A4/en not_active Withdrawn
- 1996-08-30 AU AU71090/96A patent/AU709828B2/en not_active Ceased
- 1996-08-30 AU AU69048/96A patent/AU6904896A/en not_active Abandoned
- 1996-08-30 JP JP9510549A patent/JP2000501067A/en active Pending
- 1996-08-30 JP JP9510664A patent/JP2000507805A/en active Pending
- 1996-08-30 CA CA002246117A patent/CA2246117A1/en not_active Abandoned
- 1996-08-30 BR BR9610214A patent/BR9610214A/en not_active Application Discontinuation
- 1996-08-30 CA CA002230540A patent/CA2230540A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
See also references of EP0850057A4 * |
SMITH ET AL.: "Cryptophycin: A new antimicrotubule agent active against Drug-resistant Cells.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 54, 15 July 1994 (1994-07-15), US, pages 3779 - 3784, XP002153401, ISSN: 0008-5472 * |
TRIMURTULU ET AL., J. AM. CHEM. SOC., vol. 116, 1994, pages 4729 - 4737, XP002159594 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869786A1 (en) * | 1995-12-22 | 1998-10-14 | Eli Lilly And Company | Pharmaceutical compounds |
EP0869786A4 (en) * | 1995-12-22 | 1999-04-14 | Lilly Co Eli | Pharmaceutical compounds |
EP0957912A1 (en) * | 1996-08-30 | 1999-11-24 | Eli Lilly And Company | Pharmaceutical compounds |
US6680311B1 (en) | 1996-08-30 | 2004-01-20 | Eli Lilly And Company | Cryptophycin compounds |
EP0932601A1 (en) * | 1996-08-30 | 1999-08-04 | Eli Lilly And Company | Process for preparing pharmaceutical compounds |
EP0934065A1 (en) * | 1996-08-30 | 1999-08-11 | Eli Lilly And Company | Pharmaceutical compounds |
EP0934065A4 (en) * | 1996-08-30 | 2000-10-11 | Lilly Co Eli | Pharmaceutical compounds |
EP0957912A4 (en) * | 1996-08-30 | 1999-12-22 | ||
US6133457A (en) * | 1996-08-30 | 2000-10-17 | Eli Lilly And Company | Process for preparing pharmaceutical compounds |
EP0932601A4 (en) * | 1996-08-30 | 2000-02-02 | Lilly Co Eli | Process for preparing pharmaceutical compounds |
EP0929556A4 (en) * | 1996-09-06 | 2001-04-18 | Lilly Co Eli | Process and novel intermediates |
WO1998009974A1 (en) * | 1996-09-06 | 1998-03-12 | Eli Lilly And Company | Process and novel intermediates |
EP0929556A1 (en) * | 1996-09-06 | 1999-07-21 | Eli Lilly And Company | Process and novel intermediates |
US6020512A (en) * | 1996-09-06 | 2000-02-01 | Eli Lilly And Company | Process and novel intermediates |
WO1998009601A2 (en) * | 1996-09-06 | 1998-03-12 | Eli Lilly And Company | Process to prepare pharmaceutical compounds |
EP0975610A4 (en) * | 1997-02-26 | 2000-05-17 | Lilly Co Eli | Tripeptide and tetrapeptide pharmaceutical compounds |
EP0975610A1 (en) * | 1997-02-26 | 2000-02-02 | Eli Lilly And Company | Tripeptide and tetrapeptide pharmaceutical compounds |
US6143909A (en) * | 1997-02-26 | 2000-11-07 | Eli Lilly And Company | Selective epoxidation process for preparing pharmaceutical compounds |
EP0861838A3 (en) * | 1997-02-26 | 1998-12-09 | Eli Lilly And Company | Process and intermediates for preparing cryptophycin compounds |
EP0861838A2 (en) * | 1997-02-26 | 1998-09-02 | Eli Lilly And Company | Process and intermediates for preparing cryptophycin compounds |
US6103913A (en) * | 1998-10-16 | 2000-08-15 | Eli Lilly And Company | Process for preparing enollactone derivatives |
US6376230B1 (en) | 1998-10-16 | 2002-04-23 | Eli Lilly And Company | Stereoselective process for producing intermediates of cryptophycins |
EP2266607A2 (en) | 1999-10-01 | 2010-12-29 | Immunogen, Inc. | Immunoconjugates for treating cancer |
EP2289549A2 (en) | 1999-10-01 | 2011-03-02 | Immunogen, Inc. | Immunoconjugates for treating cancer |
WO2003077906A1 (en) * | 2002-03-18 | 2003-09-25 | Nihon University | Cyclic etheramine derivatives as medicaments for malignant tumors |
EP1751279A2 (en) * | 2004-05-05 | 2007-02-14 | Regents Of The University Of Minnesota | Nucleic acids and polypeptides involved in the production of cryptophycin |
EP1751279A4 (en) * | 2004-05-05 | 2008-03-19 | Univ Minnesota | Nucleic acids and polypeptides involved in the production of cryptophycin |
US7662599B2 (en) | 2004-05-05 | 2010-02-16 | Regents Of The University Of Minnesota | Nucleic acids and polypeptides involved in the production of cryptophycin |
Also Published As
Publication number | Publication date |
---|---|
CA2230540A1 (en) | 1997-03-06 |
EP0850057A4 (en) | 2001-04-11 |
AU6904896A (en) | 1997-03-19 |
WO1997008334A1 (en) | 1997-03-06 |
AU7109096A (en) | 1997-03-19 |
EP0850316A4 (en) | 2000-08-23 |
CA2246117A1 (en) | 1997-03-06 |
BR9610214A (en) | 1999-06-15 |
EP0850057A1 (en) | 1998-07-01 |
EP0850316A1 (en) | 1998-07-01 |
JP2000501067A (en) | 2000-02-02 |
AU709828B2 (en) | 1999-09-09 |
JP2000507805A (en) | 2000-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997007798A1 (en) | Pharmaceutical compounds | |
AU695873B2 (en) | New cryptophycins | |
US6680311B1 (en) | Cryptophycin compounds | |
AU723652B2 (en) | New cryptophycins from synthesis | |
WO1998008506A1 (en) | Pharmaceutical compounds | |
EP0934065B1 (en) | Novel cryptophycin derivatives as anti-neoplastic agents | |
US5952298A (en) | Cryptophycins | |
WO1996039829A9 (en) | New cryptophycins | |
EP0923564A1 (en) | Pharmaceutical compounds | |
US20020128185A1 (en) | Pharmaceutical compounds | |
EP0792875B1 (en) | Cryptophycin derivatives and their use as anti-microtubule agents | |
US5955423A (en) | Cryptophycins | |
MXPA98001604A (en) | Farmaceuti compounds | |
AU716025B2 (en) | New cryptophycins | |
RU2195458C2 (en) | Cryptoficine compound, pharmaceutical composition, method of inhibition of cell proliferation and method of pathological state relief | |
CA2214565C (en) | New cryptophycins from synthesis | |
KR20000035919A (en) | Pharmaceutical compounds | |
MXPA99001825A (en) | Pharmaceutical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2230540 Country of ref document: CA Ref country code: CA Ref document number: 2230540 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996929780 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 510549 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/001604 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1996929780 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996929780 Country of ref document: EP |